Every material Form 8-K ResMed filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
At its November 19, 2025 annual meeting, ResMed stockholders approved amendments adding 2,400,000 shares to the 2009 Incentive Award Plan and 3,000,000 shares to the 2018 Employee Stock Purchase Plan, and elected eleven directors. Director Richard Sulpizio did not seek re-election, and the board reduced its size from twelve seats to eleven. The added shares increase the pool available for employee equity awards and stock purchases.
2009 Plan amendment: 2,400,000 additional shares, elimination of the fixed term, and authorization of incentive stock options
ESPP amendment: 3,000,000 additional shares, elimination of the fixed term, and tax-qualified options under Section 423
Say-on-pay advisory vote: 98,435,762 for, 11,004,916 against, 236,395 abstain
KPMG LLP ratified as independent auditor for fiscal year ending June 30, 2026: 103,397,962 for, 10,908,581 against
ResMed reported first-quarter fiscal 2026 results with revenue up 9% to $1.3 billion and diluted earnings per share of $2.37, up 12% from $2.11 a year earlier. The company also declared a quarterly dividend of $0.60 per share, payable December 18, 2025, which is the figure shareholders will receive per common share.
Revenue rose 9% to $1.3 billion ($1,335.6 million), or 8% on a constant currency basis.
Diluted EPS was $2.37 versus $2.11; non-GAAP diluted EPS was $2.55 versus $2.20, up 16%.
Restructuring charges of $16 million were recorded following company-wide workforce planning.
Quarterly cash dividend of $0.60 per share; record date November 13, 2025; ex-dividend date November 12, 2025.
ResMed elected Nicole Mowad-Nassar, senior vice president at AbbVie, to its board effective August 15, 2025. Director Richard Sulpizio, who has served since 2005, will not stand for reelection and will retire at the November 19, 2025 annual meeting. The filing does not describe any financial effect of these board changes.
Nicole Mowad-Nassar elected August 15, 2025, with a term running to the 2025 annual meeting on November 19, 2025; she joins the Compensation and Leadership Development Committee
Mowad-Nassar is SVP at AbbVie and president of specialty and U.S. therapeutics operations, a role held since July 2023
Richard Sulpizio, a director since 2005, will retire at the 2025 annual meeting; the filing says his decision is not due to any disagreement with ResMed
Non-executive director cash retainer increases to $75,000 for fiscal year 2026, as approved by the board in May 2025
ResMed said its chief commercial officer for the residential care software business, Bobby Ghoshal, notified the company on July 28, 2025 that he intends to resign effective August 1, 2025, to become chief operating officer of a software company outside its industry. The filing does not name a successor or describe any financial impact.
Bobby Ghoshal, chief commercial officer of the residential care software business (RCS), gave notice on July 28, 2025.
Resignation is effective August 1, 2025.
He plans to join a software company in a non-competitive industry as chief operating officer.
The filing does not name a replacement or report any financial effect.
ResMed reported fourth-quarter fiscal 2025 results for the quarter ended June 30, 2025, with revenue up 10% to $1.3 billion and diluted earnings per share up 30% to $2.58. The company also declared a quarterly dividend of $0.60 per share, a 13% increase, payable September 18, 2025 to holders of record on August 14, 2025.
Q4 revenue $1,348.0 million, up 10% (9% constant currency); income from operations up 19% to $454.5 million
Q4 diluted EPS $2.58 vs. $1.98 a year earlier; non-GAAP diluted EPS $2.55 vs. $2.08
Full-year revenue $5.1 billion, up 10%; full-year diluted EPS $9.51 vs. $6.92
Quarterly dividend $0.60 per share; ex-dividend date August 13, 2025
ResMed reported results for the quarter ended March 31, 2025, with revenue up 8% to $1.3 billion and diluted EPS of $2.48, up from $2.04 a year earlier. The board also declared a $0.53 per share quarterly dividend, with a May 8, 2025 record date and a June 12, 2025 payment date.
Revenue $1,291.7 million, up 8% (9% constant currency); gross margin 59.3%, up 140 basis points
Income from operations $426.3 million, up 14%; net income $365.0 million, up 21%
Quarterly dividend of $0.53 per share; ex-dividend date May 7, 2025, payable June 12, 2025
Operating cash flow $579 million, including $107 million in IRS tax refunds
ResMed reported fiscal second-quarter 2025 results for the quarter ended December 31, 2024, with revenue up 10% to $1.3 billion and diluted earnings per share of $2.34, up from $1.42. The prior-year quarter included $64.2 million of restructuring charges, which lifts the year-over-year comparison; non-GAAP diluted EPS rose 29% to $2.43. The board also declared a quarterly dividend of $0.53 per share.
Revenue rose 10% to $1.3 billion ($1,282.1 million); gross margin improved 300 basis points to 58.6%.
Diluted EPS was $2.34 versus $1.42; non-GAAP diluted EPS was $2.43 versus $1.88.
Operating cash flow was $309 million; $78 million was paid in dividends and $75 million was spent on share repurchases.
Quarterly dividend of $0.53 per share has a February 13, 2025 record date and is payable March 20, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ResMed filing is on SEC EDGAR ↗. 8-K briefs of other companies →